系统性红斑狼疮伴动脉粥样硬化危险因素研究进展
Advances in the Study of Risk Factors for Systemic Lupus Erythematosus with Atherosclerosis
DOI: 10.12677/ACM.2023.1371494, PDF,    科研立项经费支持
作者: 崔天晓, 叶·叶尔丁其木克, 米扎尼也古丽·卡哈尔, 崔 挺, 张继云*:新疆医科大学第二附属医院风湿免疫科,新疆 乌鲁木齐
关键词: 系统性红斑狼疮动脉粥样硬化危险因素Systemic Lupus Erythematosus Atherosclerosis Risk Factor
摘要: 系统性红斑狼疮(Systemic Lupus Erythematosus, SLE)好发于育龄女性,是以自身免疫抗体和免疫复合物为媒介,慢性炎症性组织损伤为主要表现的一种自身免疫性疾病。它的炎症损伤可涉及到全身各个脏器,其中以累及心血管系统所引起的不良影响是最严重的。大量的研究资料显示SLE患者的前期死亡原因主要是疾病活动,后期则往往发展成动脉粥样硬化(Atherosclerosis, AS),从而使死亡率升高。经典的危险因素如肥胖、吸烟等可以加速AS进展,但对非传统危险因素控制并采取全面干预措施亦能改善SLE病人的预后,降低死亡率。因此SLE治疗中必须重视血管病变的防治。本文将重点讨论近期系统性红斑狼疮伴动脉粥样硬化(SLE-AS)危险因素的研究进展。
Abstract: Systemic Lupus Erythematosus (SLE) occurs in women of childbearing age and is an autoimmune disease with chronic inflammatory tissue damage mediated by autoimmune antibodies and im-mune complexes. Its inflammatory damage can involve all organs of the body, with the most serious adverse effects caused by the involvement of the cardiovascular system. A large number of studies have shown that the main cause of death in SLE patients is disease activity in the early stages, while the later stages tend to develop atherosclerosis (AS), which increases mortality. While classical risk factors such as obesity and smoking can accelerate the progression of AS, control of non-traditional risk factors and comprehensive interventions can also improve the prognosis of SLE patients and reduce mortality. Therefore, the prevention and treatment of vascular lesions must be emphasized in the management of SLE. In this article, we will focus on recent advances in the study of risk fac-tors for SLE with atherosclerosis (SLE-AS).
文章引用:崔天晓, 叶·叶尔丁其木克, 米扎尼也古丽·卡哈尔, 崔挺, 张继云. 系统性红斑狼疮伴动脉粥样硬化危险因素研究进展[J]. 临床医学进展, 2023, 13(7): 10700-10706. https://doi.org/10.12677/ACM.2023.1371494

参考文献

[1] Patiño-Trives, A.M., Pérez-Sánchez, C., Pérez-Sánchez, L., et al. (2021) Anti-dsDNA Antibodies Increase the Cardio-vascular Risk in Systemic Lupus Erythematosus Promoting a Distinctive Immune and Vascular Activation. Arterioscle-rosis, Thrombosis, and Vascular Biology, 41, 2417-2430. [Google Scholar] [CrossRef
[2] Gao, N., Kong, M., Li, X., et al. (2022) Systemic Lupus Er-ythematosus and Cardiovascular Disease: A Mendelian Randomization Study. Frontiers in Immunology, 13, Article ID: 908831. [Google Scholar] [CrossRef] [PubMed]
[3] Oliveira, C.B. and Kaplan, M.J. (2022) Cardiovascular Disease Risk and Pathogenesis in Systemic Lupus Erythematosus. Seminars in Immunopathology, 44, 309-324. [Google Scholar] [CrossRef] [PubMed]
[4] Frostegård, J. (2023) Systemic Lupus Erythematosus and Car-diovascular Disease. Journal of Internal Medicine, 293, 48-62. [Google Scholar] [CrossRef] [PubMed]
[5] Radin, M., Cecchi, I., Roccatello, D., et al. (2018) Prevalence and Thrombotic Risk Assessment of Anti-β2 Glycoprotein I Domain I Antibodies: A Systematic Review. Seminars in Thrombosis and Hemostasis, 44, 466-474. [Google Scholar] [CrossRef] [PubMed]
[6] Fierro, J.J., Velásquez, M., Cadavid, A.P., et al. (2022) Effects of Anti-Beta 2-Glycoprotein 1 Antibodies and Its Association with Pregnancy-Related Morbidity in Antiphospholipid Syn-drome. American Journal of Reproductive Immunology, 87, e13509. [Google Scholar] [CrossRef] [PubMed]
[7] Cinoku, I.I., Mavragani, C.P. and Moutsopoulos, H.M. (2020) Atherosclerosis: Beyond the Lipid Storage Hypothesis. The Role of Autoimmunity. European Journal of Clinical Investigation, 50, e13195. [Google Scholar] [CrossRef] [PubMed]
[8] Monjezi, M.R., Fouladseresht, H., Farjadian, S., et al. (2021) T Cell Prolif-erative Responses and IgG Antibodies to β2GPI in Patients with Diabetes and Atherosclerosis. Endocrine, Metabolic & Immune Disorders—Drug Targets, 21, 495-503. [Google Scholar] [CrossRef] [PubMed]
[9] Kuang, W., Li, Y., Liu, G., et al. (2022) Correlation between Serum β2-GPI/oxLDL and the Risk of Cerebral Infarction in Patients with T2DM. Frontiers in Surgery, 9, Ar-ticle ID: 930701. [Google Scholar] [CrossRef] [PubMed]
[10] Sun, J., Lundström, S.L., Zhang, B., et al. (2018) IgM Antibodies against Phosphorylcholine Promote Polarization of T Regulatory Cells from Patients with Atherosclerot-ic Plaques, Systemic Lupus Erythematosus and Healthy Donors. Atherosclerosis, 268, 36-48. [Google Scholar] [CrossRef] [PubMed]
[11] 王君君, 章帆, 姜丰, 等. 动脉粥样硬化指数与血清抗心磷脂抗体及抗β2糖蛋白1抗体水平的相关性研究[J]. 中国动脉硬化杂志, 2019, 27(7): 611-614.
[12] 赵维庆, 刘爽, 付李胤且, 等. 系统性红斑狼疮患者血清AECA检测临床意义的再评价[J]. 国际检验医学杂志, 2022, 43(2): 134-142.
[13] Cieślik, P., Semik-Grabarczyk, E., Hrycek, A., et al. (2022) The Impact of Anti-Endothelial Cell Antibodies (AECAs) on the Development of Blood Vessel Damage in Patients with Systemic Lupus Erythematosus: The Preliminary Study. Rheumatology International, 42, 791-801. [Google Scholar] [CrossRef] [PubMed]
[14] 高岭, 王莉, 殷丝雨, 等. 系统性红斑狼疮患儿血清抗内皮细胞抗体检测的临床意义[J]. 现代免疫学, 2021, 41(5): 392-396.
[15] Morand, E.F., Furie, R., Tanaka, Y., et al. (2020) Trial of Anifrolumab in Active Systemic Lupus Ery-thematosus. The New England Journal of Medicine, 382, 211-221. [Google Scholar] [CrossRef
[16] Pattanaik, S.S., Panda, A.K., Pati, A., et al. (2022) Role of Interleu-kin-6 and Interferon-α in Systemic Lupus Erythematosus: A Case-Control Study and Meta-Analysis. Lupus, 31, 1094-1103. [Google Scholar] [CrossRef] [PubMed]
[17] Lai, J.H., Hung, L.F., Huang, C.Y., et al. (2021) Mitochondrial Protein CMPK2 Regulates IFN Alpha-Enhanced Foam Cell Formation, Potentially Contributing to Premature Athero-sclerosis in SLE. Arthritis Research & Therapy, 23, Article No. 120. [Google Scholar] [CrossRef] [PubMed]
[18] Casey, K.A., Smith, M.A., Sinibaldi, D., et al. (2021) Modula-tion of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus. Arthritis & Rheumatology, 73, 459-471. [Google Scholar] [CrossRef] [PubMed]
[19] Fayed, A., El Menyawi, M.M., Ghanema, M., et al. (2020) Measurement of Serum Interferon Alpha in Egyptian Patients with Systemic Lupus Erythematosus and Evaluation of Its Effect on Disease Activity: A Case-Control Study. Reumatismo, 72, 145-153. [Google Scholar] [CrossRef] [PubMed]
[20] Zhang, W., Borcherding, N. and Kolb, R. (2020) IL-1 Signal-ing in Tumor Microenvironment. In: Birbrair, A., Ed., Tumor Microenvironment, Springer, Berlin, 1-23. [Google Scholar] [CrossRef] [PubMed]
[21] Zhou, L. and Todorovic, V. (2021) Interleukin-36: Structure, Signaling and Function. In: Atassi, M.Z., Ed., Protein Reviews, Springer, Berlin, 191-210. [Google Scholar] [CrossRef] [PubMed]
[22] Duarte, A.L., Dantas, A.T., de Ataíde Mariz, H., et al. (2013) De-creased Serum Interleukin 27 in Brazilian Systemic Lupus Erythematosus Patients. Molecular Biology Reports, 40, 4889-4892. [Google Scholar] [CrossRef] [PubMed]
[23] Ryu, H. and Chung, Y. (2018) Dyslipidemia Pro-motes Germinal Center Reactions via IL-27. BMB Reports, 51, 371-372. [Google Scholar] [CrossRef
[24] Liu, Q., Fan, J., Bai, J., et al. (2018) IL-34 Promotes Foam Cell Formation by Enhancing CD36 Expression through p38 MAPK Pathway. Scientific Reports, 8, Article No. 17347. [Google Scholar] [CrossRef] [PubMed]
[25] Marczynski, P., Meineck, M., Xia, N., et al. (2021) Vascular In-flammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation. International Journal of Mo-lecular Sciences, 22, Article No. 2291. [Google Scholar] [CrossRef] [PubMed]
[26] El-Banna, H.S., El Khouly, R.M. and Gado, S.E. (2020) Elevated Se-rum Interleukin-34 Level in Juvenile Systemic Lupus Erythematosus and Disease Activity. Clinical Rheumatology, 39, 1627-1632. [Google Scholar] [CrossRef] [PubMed]
[27] Wu, Y.R., Hsing, C.H., Chiu, C.J., et al. (2022) Roles of IL-1 and IL-10 Family Cytokines in the Progression of Systemic Lupus Erythematosus: Friends or Foes? IUBMB Life, 74, 143-156. [Google Scholar] [CrossRef] [PubMed]
[28] Mohammadi, S., Ebadpour, M.R., Sedighi, S., et al. (2017) Gluco-corticoid-Induced Leucine Zipper Expression Is Associated with Response to Treatment and Immunoregulation in Sys-temic Lupus Erythematosus. Clinical Rheumatology, 36, 1765-1772. [Google Scholar] [CrossRef] [PubMed]
[29] Yamamoto, E.A., Nguyen, J.K., Liu, J., et al. (2020) Low Levels of Vitamin D Promote Memory B Cells in Lupus. Nutrients, 12, Article No. 291. [Google Scholar] [CrossRef] [PubMed]
[30] Mellor-Pita, S., Tutor-Ureta, P., Rosado, S., et al. (2019) Calcium and Vitamin D Supplement Intake May Increase Arterial Stiffness in Systemic Lupus Erythematosus Patients. Clinical Rheumatology, 38, 1177-1186. [Google Scholar] [CrossRef] [PubMed]
[31] Tabra, S., Abdelnabi, H.H., Darwish, N., et al. (2020) Juvenile Lupus and Serum Vitamin D Levels: A Cross-Sectional Study. Lupus, 29, 1752-1758. [Google Scholar] [CrossRef] [PubMed]
[32] Lee, T.W., Kao, Y.H., Chen, Y.J., et al. (2019) Therapeutic Po-tential of Vitamin D in AGE/RAGE-Related Cardiovascular Diseases. Cellular and Molecular Life Sciences, 76, 4103-4115. [Google Scholar] [CrossRef] [PubMed]
[33] Reynolds, J.A., Haque, S., Williamson, K., et al. (2016) Vitamin D Improves Endothelial Dysfunction and Restores Myeloid Angiogenic Cell Function via Reduced CXCL-10 Expression in Systemic Lupus Erythematosus. Scientific Reports, 6, Article No. 22341. [Google Scholar] [CrossRef] [PubMed]
[34] Oz, F., Cizgici, A.Y., Oflaz, H., et al. (2013) Impact of Vitamin D Insuffi-ciency on the Epicardial Coronary Flow Velocity and Endothelial Function. Coronary Artery Disease, 24, 392-397. [Google Scholar] [CrossRef
[35] Islam, M.A., Shahad SaifAlam, S.S. and PrzemyslawHas-san, R. (2019) Vitamin D Status in Patients with Systemic Lupus Erythematosus (SLE): A Systematic Review and Me-ta-Analysis. Autoimmunity Reviews, 18, Article ID: 102392. [Google Scholar] [CrossRef] [PubMed]
[36] Tselios, K., Koumaras, C., Gladman, D.D., et al. (2016) Dyslipidemia in Systemic Lupus Erythematosus: Just Another Comorbidity? Seminars in Arthritis and Rheumatism, 45, 604-610. [Google Scholar] [CrossRef] [PubMed]
[37] Zhou, B., Xia, Y. and She, J. (2020) Dysregulated Serum Lipid Profile and Its Correlation to Disease Activity in Young Female Adults Diagnosed with Systemic Lupus Er-ythematosus: A Cross-Sectional Study. Lipids in Health and Disease, 19, Article No. 40. [Google Scholar] [CrossRef] [PubMed]
[38] Ronda, N., Favari, E., Borghi, M.O., et al. (2014) Impaired Se-rum Cholesterol Efflux Capacity in Rheumatoid Arthritis and Systemic Lupus Erythematosus. Annals of Rheumatic Dis-eases, 73, 609-615. [Google Scholar] [CrossRef] [PubMed]
[39] Olusi, S.O. and George, S. (2011) Prevalence of LDL Atherogenic Phenotype in Patients with Systemic Lupus Erythematosus. Vascular Health and Risk Management, 7, 75-80. [Google Scholar] [CrossRef
[40] Kim, S.Y., Yu, M., Morin, E.E., et al. (2020) High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy. Arthritis & Rheumatology, 72, 20-30. [Google Scholar] [CrossRef] [PubMed]
[41] Kotur-Stevuljević, J., Vekić, J., Stefanović, A., et al. (2020) Paraoxonase 1 and Atherosclerosis-Related Diseases. Bio- factors, 46, 193-205. [Google Scholar] [CrossRef] [PubMed]
[42] Cochran, B.J., Ong, K.L., Manandhar, B., et al. (2021) APOA1: A Protein with Multiple Therapeutic Functions. Current Athero-sclerosis Reports, 23, Article No. 11. [Google Scholar] [CrossRef] [PubMed]
[43] Hevia, A., Milani, C., Lopez, P., et al. (2014) Intestinal Dysbiosis Associated with Systemic Lupus Erythematosus. mBio, 5, e01548-14. [Google Scholar] [CrossRef
[44] Guo, M., Wang, H., Xu, S., et al. (2020) Alteration in Gut Microbiota Is Associated with Dysregulation of Cytokines and Glucocorticoid Therapy in Systemic Lupus Erythematosus. Gut Microbes, 11, 1758-1773. [Google Scholar] [CrossRef] [PubMed]
[45] Li, Y., Wang, H.F., Li, X., et al. (2019) Disordered Intestinal Microbes Are Associated with the Activity of Systemic Lupus Erythematosus. Clinical Science (London), 133, 821-838. [Google Scholar] [CrossRef
[46] Brown, E.M., Kenny, D.J. and Xavier, R.J. (2019) Gut Microbiota Reg-ulation of T Cells during Inflammation and Autoimmunity. Annual Review of Immunology, 37, 599-624. [Google Scholar] [CrossRef] [PubMed]
[47] Ruff, W.E., Dehner, C., Kim, W.J., et al. (2019) Pathogenic Autoreactive T and B Cells Cross-React with Mimotopes Expressed by a Common Human Gut Commensal to Trigger Autoimmunity. Cell Host & Microbe, 26, 100-113.e8. [Google Scholar] [CrossRef] [PubMed]
[48] Kasselman, L.J., Vernice, N.A., DeLeon, J., et al. (2018) The Gut Microbiome and Elevated Cardiovascular Risk in Obesity and Autoimmunity. Atherosclerosis, 271, 203-213. [Google Scholar] [CrossRef] [PubMed]
[49] Yoshida, N., Emoto, T., Yamashita, T., et al. (2018) Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Athero-sclerosis. Circulation, 138, 2486-2498. [Google Scholar] [CrossRef